Latest SCLC Stories
MADRID, January 13, 2015 /PRNewswire/ -- - The unparalleled results obtained in the Phase Ib study support the start of a head-to-head study in
Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers
Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES, Sept.
Report Stems From National Grassroots Advocacy To Require New Strategic Plans Of Action To Address Deadliest Cancers WASHINGTON, July 1, 2014 /PRNewswire-USNewswire/ -- Today the National Cancer
Two antidepressants that aren’t often prescribed to patients could soon be recommended to serve a completely different purpose; ward off small cell lung cancer (SCLC).
Although numerous randomized clinical trials have demonstrated a benefit of chemotherapy for patients with small-cell lung cancer (SCLC), these trials have predominantly compared different chemotherapy regimens rather than comparing chemotherapy to best supportive care.
NEW YORK and SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- Polaris Group (Polaris) and The Ludwig Institute for Cancer Research (LICR) today announced the enrollment of the first patient in a Phase 2 clinical trial evaluating ADI-PEG 20 in the treatment of small cell lung cancer (SCLC).
MicroRNA study provides biomarker for survival in small cell lung cancer.
SOUTH SAN FRANCISCO, June 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced a clinical and regulatory update on its lead product candidate, picoplatin.
- Withering but not falling off, as a blossom that persists on a twig after flowering.